Pr Yohann Loriot
- Spécialité
- Oncologue médical, expert urologie
- Titre
- Chef adjoint du département des Essais Précoces (DITEP)
- Hôpital
- Gustave Roussy (Villejuif)
- Derniers articles
-
- Erdafitinib versus Chemotherapy in Fibroblast Growth Factor Receptor-Altered Advanced or Metastatic Urothelial Cancer After Progression on Anti-programmed Death-(Ligand) 1 Therapy: An Exploratory Analysis of the Asian Subpopulation in the THOR Phase 3 Study. (1 août 2025)
- SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma. (29 juil. 2025)
- Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancers. (29 juil. 2025)
- Plain language summary of the THOR Cohort 1 study comparing treatment with erdafitinib or chemotherapy in advanced or metastatic urothelial cancer. (1 juil. 2025)
- Baseline CT-derived tumor burden and liquid biopsy as biomarkers to predict survival in patients with metastatic solid cancer. (7 juin 2025)